Business
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded first quarter 2026 with approximately $7.3 million in cash while continuing evaluation of strategic alternatives to maximize shareholder value FRAMINGHAM, MA / ACCESS Newswire / May 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform.Recent HighlightsGenerated robust translational data supporting the DNase I platform across multiple oncology settingsCompleted process improvement and analytical development activities supporting future clinical manufacturing readinessEstablished translational and biomarker insights intended to help inform and de-risk future clinical trial designCollaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma\"We entered 2026 with a clear focus on advancing the translational, manufacturing and clinical foundation of our DNase I platform while maintaining financial discipline,\" said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. \"During the quarter, we achieved important progress across investigator-initiated studies, translational research and manufacturing readiness activities. We believe the growing body of translational evidence supporting NET-targeting approaches, combined with the expanding understanding of NETs as drivers of tumor progression, immune suppression and therapy resistance, continues to strengthen the potential opportunity for DNase I as a differentiated adjunctive immuno-oncology therapy across multiple cancer settings.\"Xenetic's proprietary DNase technology is being developed as a potential adjunctive therapeutic approach designed to improve the effectiveness of existing cancer treatments, including immunotherapies, through the targeting of NETs, which are increasingly...